Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02654587 |
| Title | Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) |
| Acronym | ATALANTE-1 |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | OSE Immunotherapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE |
CKB BOOST